Er-Positive, Her2-Negative Breast Cancer

SAN ANTONIO — In this video, Judy Garber, MD, MPH, discusses the results of the OlympiA trial presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — In this video, Shimoli Barot, MD, discusses the results of a study observing exceptional treatment response in patients with metastatic breast cancer presented at San Antonio Breast Cancer Symposium.

CHICAGO — Halle Moore, MD, director of breast medical oncology in the department of hematology and oncology at Cleveland Clinic Taussig Cancer Institute, spoke with Healio about findings from the ELAINE 2 study.

CHICAGO — The addition of chemotherapy to endocrine therapy did not extend OS after surgery among older patients with ER-positive, HER2-negative breast cancer with a high tumor genomic grade index.

A randomized phase 3 trial designed to evaluate elacestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer met both of its primary endpoints, according to the agent’s manufacturer.

HER2–low expression was linked to inferior progression-free survival among breast cancer patients with estrogen receptor-positive, HER2-negative metastatic disease treated with CDK4/6 inhibitors, according to research presented at ASCO 2021.